ClinicalTrials.gg
RecruitingNCT07945821TREGCHECK 103Updated Nov 18, 2026

A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of Tagmokitug and Pasritamig in Solid Tumor, sponsored by Coherus Oncology, Inc.. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Coherus Oncology, Inc. · Phase 1/2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 607 open to participants now, 975 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
2,556th of 3,024
12 · median 48
Started
2026
with 175 others
Phase 1/2
284 of 3,597
63 open now
Primary completion
2028-08
later than 688 of 969 live
Registered
3,597th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 2,556th largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 176 that started in 2026, is one of 284 in phase 1/2, reaches primary completion later than 688 of the 969 other live ones, and was the 3,597th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

607 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

601 more — sign in →

All 607 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.

03

Conditions studied

  • Solid Tumor

Keywords

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • mCRPC
  • Prostate Cancer
  • Tagmokitug
  • Prostatic Cancer, Castration-Resistant
  • Pasritamig
  • CHS-114
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • performance status (ECOG PS) of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment.

mCRPC:

  • confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted.
  • Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan.
  • Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide).
  • Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide).
  • Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase.

Key Exclusion Criteria:

  • History of prior other than the cancer under study that is progressing or has required active treatment within the past 3 years.
  • Prior exposure to anti-CCR8 antibody agents.
  • Prior allogeneic hematological stem cell transplantation or organ transplantation.

mCRPC:

  • Any known prior history of of prostate cancer (PCa).
  • Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and agents) other than ADT or ARPI within 28 days or \<5× the elimination half-life (t½), whichever is earlier, before Day 1.
  • Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy.
  • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.

Additional protocol-defined inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    mCRPC: Tagmokitug + Pasritamig

    Drug: Tagmokitug · Drug: Pasritamig

Interventions

  • DrugTagmokitug

    Specified dose on specified days.

  • Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to approximately 2.5 years

  2. Number of Participants with Dose-limiting Toxicities (DLTs)

    Time frame: Up to 56 Days

Secondary outcomes

  1. mCRPC: Prostate Specific Antigen >=50% Response Rate (PSA50) per Prostate Cancer Working Group 3 (PCWG3) Criteria

    Time frame: Up to approximately 2.5 years

  2. Objective Response Rate (ORR)

    Time frame: Up to approximately 2.5 years

  3. Disease Control Rate (DCR)

    Time frame: Up to approximately 2.5 years

  4. Duration of Response (DOR)

    Time frame: Up to approximately 2.5 years

  5. mCRPC: Radiographic Progression-free Survival (rPFS)

    Time frame: Up to approximately 2.5 years

  6. Progression-free Survival (rPFS)

    Time frame: Up to approximately 2.5 years

  7. Maximum Observed Serum Concentration of Tagmokitug (Cmax)

    Time frame: Up to approximately 2.5 years

  8. Concentration of Tagmokitug Immediately Before the Next Dose (Ctrough)

    Time frame: Up to approximately 2.5 years

  9. Number of Participants with Anti-drug Antibodies to Tagmokitug

    Time frame: Up to approximately 2.5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 21 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945821
Lead sponsor
Coherus Oncology, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Operations Team
Contact
ClinicalTrials@coherus.com
+1-800-794-5434
Study Director
study director · Coherus Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion